We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » STUDY SIZE ALONE NO LONGER DETERMINATION IN CANCER IND EXEMPTION
STUDY SIZE ALONE NO LONGER DETERMINATION IN CANCER IND EXEMPTION
January 16, 2004
The FDA will no longer base decisions on the size of a clinical cancer study alone when considering if it is exempt from investigational new drug (IND) regulations, the agency said in a revised guidance last week.